Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (TEVA), has unveiled promising new data regarding social functioning and quality of life from its Phase 3 SOLARIS trial, which evaluates TEV-'749 in adults diagnosed with schizophrenia.
During the acute treatment period of this study (Period 1), TEV-'749 showed a marked improvement in social functioning and quality of life, measured by several validated standards from the baseline to week 8. The comprehensive safety profile of TEV-'749 aligns with other approved oral olanzapine formulations, revealing no new safety concerns and no reported incidents of Post-Injection Delirium/Sedation Syndrome (PDSS) thus far.
Additionally, in vitro findings and preliminary outcomes from a Phase 1 study examining the pharmacokinetic properties of TEV-'749 confirm that its delivery method and technology could successfully mitigate the risk of PDSS.
Teva has also disclosed real-world data concerning UZEDY (risperidone), its extended-release injectable formulation designed for subcutaneous administration every one or two months for adult schizophrenia treatment, as presented at Psych Congress 2024.
Real-world evaluations of the UZEDY (risperidone) subcutaneous long-acting injectable have demonstrated high compliance levels among adults with schizophrenia. Such results emphasize its effective application, particularly for those encountering treatment-related obstacles.
